MedTrace Logo

A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

NCT04451811 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-05-28

No results posted yet for this study

Summary

This is a single center, randomized, open-label, three-way crossover, single dose, pharmacokinetic dose proportionality study of oral OPL-002 in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

OPL-002

Spray dried dispersion and tablet formulation

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Oppilan Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Richard Gregg, MD · Oppilan Pharma Ltd

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2021-02-24
Completion
2021-02-24
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451811 on ClinicalTrials.gov